Medical News

RSS

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Risk of having high blood pressure in adulthood can be detected in childhood

Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new research from New Zealand's University of Otago suggests.

9 Oct 2015

$Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study$

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Osteoporosis, a disease of progressive bone loss, affects 70 percent of the U.S. population older than age 50: one in two women--and one in five men. These individuals are at risk for fragility fractures, a break that results from a fall, or occurs in the absence of obvious trauma, and most commonly seen in the wrist, the upper arm, the hip, and the spine.

9 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

Antioxidants can increase rate of melanoma metastasis in mice

Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice. The results reinforce previous findings that antioxidants hasten the progression of lung cancer. According to Professor Martin Bergö, people with cancer or an elevated risk of developing the disease should avoid nutritional supplements that contain antioxidants.

9 Oct 2015

Ambry Genetics presents groundbreaking TP53 gene data at ASHG; TP53 linked to breast cancer

Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, has announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.

9 Oct 2015

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

To honor six cancer survivors featured in its newest international ad campaign, NanoString Technologies, Inc. will donate $6,000 to the American Cancer Society. The “Dear Cancer Researcher” participants courageously shared their personal stories of triumph to help the biotechnology company launch its newest product, nCounter SPRINT™ Profiler, a system that gives researchers the tools and opportunity to think beyond current everyday practice.

From NanoString Technologies 9 Oct 2015

Avita Medical gains two CE marks to complete skin healing portfolio

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.

9 Oct 2015

Research on investigational menopause drug wins first prize

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced it received top honors for its research on investigational drug lasofoxifene at the 26th annual North American Menopause Society (NAMS) meeting in Las Vegas last week.

9 Oct 2015

CRF Health launches new website and industry-first eCOA resource hub

CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, today launched its new website, www.crfhealth.com, which includes an industry-first online eCOA resource hub. The multimedia platform provides a wide range of webinars, eBooks, articles and videos covering the effective implementation, management and scaling of eCOA technology for global clinical trials.

9 Oct 2015

Minor hallucinations may predate Parkinson motor symptoms

About four in 10 patients with untreated Parkinson’s disease experience minor hallucinations, research shows.

8 Oct 2015

Daclizumab HYP superior to interferon in relapsing–remitting MS

The DECIDE study shows that 4-weekly daclizumab high-yield process reduces disease activity in patients with relapsing–remitting multiple sclerosis more effectively than weekly interferon beta-1a, albeit at the cost of more adverse effects.

8 Oct 2015

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF).

8 Oct 2015

JKTG Foundation announces over $160K in awards to support next generation of health policy research

Today, the Jayne Koskinas Ted Giovanis Foundation announced over $160K in awards to support the next generation of health policy research and promote better healthcare for patients. Four graduate researchers in the field of health policy and administration at Brown University, Georgetown University, Harvard University and The Johns Hopkins University received Dissertation Support Grants (DSGs) to aid their research.

8 Oct 2015

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

Bankers Healthcare Group, the leading provider of financial solutions for healthcare professionals, recently launched a company-wide diabetes awareness campaign that will run through November.

8 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

Up to 1 billion people could be at risk of going blind by 2050, say researchers

Up to 1 billion people could be at risk of blindness by the middle of the century if an emerging short-sightedness (myopia) epidemic is ignored say researchers at the Brien Holden Vision Institute.

8 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer.

8 Oct 2015

Medical News

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Risk of having high blood pressure in adulthood can be detected in childhood

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Antioxidants can increase rate of melanoma metastasis in mice

Ambry Genetics presents groundbreaking TP53 gene data at ASHG; TP53 linked to breast cancer

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

Avita Medical gains two CE marks to complete skin healing portfolio

Research on investigational menopause drug wins first prize

CRF Health launches new website and industry-first eCOA resource hub

Minor hallucinations may predate Parkinson motor symptoms

Daclizumab HYP superior to interferon in relapsing–remitting MS

Celtaxsys commences acebilustat phase 2 trial in patients with cystic fibrosis in US

JKTG Foundation announces over $160K in awards to support next generation of health policy research

Bankers Healthcare Group's company-wide diabetes awareness campaign to run through November

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

Up to 1 billion people could be at risk of going blind by 2050, say researchers

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News